EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HBx hijacks the miR‐19a‐3p/BAMBI/TGF‐β1 axis to impair the anti‐tumour activity of CD4 + T cells in diffuse large B‐cell lymphoma

Xuecong Guo, Jianguo Li, Xiaofei Bai, Yinghui Huang, Xu Xu, Jiabang Yang, Zhenghao Sun, Wangcheng Zhu, Xudong Guo, Jie Chen, Jiuhong Kang

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Xuecong Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shang…. Hauptthemen laut MEDLINE: MicroRNAs, Lymphoma, Large B-Cell, Diffuse, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta1. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B virus (HBV) is clinically associated with poor prognosis in diffuse large B‐cell lymphoma (DLBCL), while cellular communication in the tumour microenvironment (TME) is recognized as a critical driver of tumour progression. Nevertheless, whether HBV infection mediates DLBCL cell‐immune cell crosstalk remains undefined, with the precise mechanisms and associated key molecules remaining elusive.

Methods

SsGSEA, Cox regression (univariate/multivariate), WGCNA, and Kaplan–Meier analyses identified prognostic immune subsets and miRNAs in HBV + DLBCL. Dual luciferase assay, qRT‐PCR, western blot, ChIP, Co‐IP, flow cytometry, enzyme‐linked immunosorbent assay, immunohistochemistry, and murine models were employed together to evaluate CD4 + T cell dysfunction in vitro and in vivo. ScRNA‐seq analyses encompassed clustering, pseudotemporal trajectory, and ligand–receptor networks to decode TME dynamics.

Results

TME profiling identified diminished CD4⁺ T cell infiltration as an independent predictor of poor survival in HBV⁺ DLBCL. Mechanistically, HBx‐mediated down‐regulation of miR‐19a‐3p activated the BAMBI/Wnt signalling pathway, thereby enhancing TGF‐β1 secretion and suppressing the anti‐tumour activity of CD4 + T cells. Single‐cell analysis revealed that BAMBI high DLBCL cells engage CD4 + T cells via TGFB1‐TGFBR2 pair, with TGFBR2 enriched in exhausted subsets of CD4 + T cells and shaping their dysfunctional fate. Therapeutic restoration of miR‐19a‐3p or blockade of TGF‐β reinforced the CD4⁺ T cell anti‐tumour activity and restrained the progression of HBx‐overexpressing DLBCL in vivo.

Conclusions

HBx promoted TGF‐β1 hypersecretion via miR‐19a‐3p repression‐mediated Wnt/β‐catenin activation, directly driving CD4 + T cell depletion and functional exhaustion in DLBCL. Our work provided important insights into the immune determinants of poor prognosis in HBV + DLBCL, highlighting the pivotal role of CD4 + T cell dysfunction in driving disease progression and adverse clinical outcomes. Highlights Reduced CD4 + T cell enrichment in the TME predicted poor survival in HBV + DLBCL. Down‐regulation of miR‐19a‐3p by HBx activated the BAMBI‐mediated Wnt signalling, amplifying TGF‐β1 secretion to suppress anti‐tumour activity of CD4⁺ T cells. The TGF‐B1/TGFBR2 pair mediated the HBV + DLBCL‐CD4 + T cell communication. Targeting TGF‐β or miR‐19a‐3p improved CD4 + T cell immunity to suppress HBV + DLBCL progression

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLymphoma, Large B-Cell, DiffuseCD4-Positive T-LymphocytesTransforming Growth Factor beta1Viral Regulatory and Accessory ProteinsTrans-ActivatorsHumansAnimalsMiceTumor MicroenvironmentHepatitis B virusMaleFemaleHepatitis B

Stichwörter der Autor:innen

CD4+ T cellsdiffuse large B‐cell lymphoma (DLBCL)hepatitis B virus (HBV)prognosis

Substanzen

MicroRNAsTransforming Growth Factor beta1MIRN19A microRNA, humanViral Regulatory and Accessory Proteinshepatitis B virus X proteinTrans-Activators

Autor:innen und Institutionen

  • Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science…
  • Department of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Department of Life Sciences, Imperial College London, London, UK.

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai Municipality
  • Fundamental Research Funds for the Central Universities
  • The Peak Disciplines of Institutions of Higher Learning in Shanghai

Zitieren

APA

Guo, X., Li, J., Bai, X., Huang, Y., Xu, X., Yang, J., Sun, Z., Zhu, W., Guo, X., Chen, J., & Kang, J. (2026). HBx hijacks the miR‐19a‐3p/BAMBI/TGF‐β1 axis to impair the anti‐tumour activity of CD4 + T cells in diffuse large B‐cell lymphoma. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70578

Vancouver

Guo X, Li J, Bai X, Huang Y, Xu X, Yang J, et al. HBx hijacks the miR‐19a‐3p/BAMBI/TGF‐β1 axis to impair the anti‐tumour activity of CD4 + T cells in diffuse large B‐cell lymphoma. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70578

BibTeX
@article{Guo2026,
  author = {Guo, Xuecong and Li, Jianguo and Bai, Xiaofei and Huang, Yinghui and Xu, Xu and Yang, Jiabang and Sun, Zhenghao and Zhu, Wangcheng and Guo, Xudong and Chen, Jie and Kang, Jiuhong},
  title = {HBx hijacks the miR‐19a‐3p/BAMBI/TGF‐β1 axis to impair the anti‐tumour activity of CD4 + T cells in diffuse large B‐cell lymphoma},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70578}
}
Kostenlos starten →